Morgan Stanley analyst Patrick Wood resumed coverage of Edwards Lifesciences with an Equal Weight rating and $70 price target Edwards is “a great business, with an exceptional balance sheet,” and it stands to benefit from TCT catalysts, says the firm, which adds that it is “bullish on TMTT.” However, with slower TAVR growth appreciated by investors, the analyst thinks “shares are priced just right.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences call volume above normal and directionally bullish
- Edwards Lifesciences price target lowered to $75 from $85 at RBC Capital
- Edwards Lifesciences price target lowered to $66 from $77 at Canaccord
- Edwards Lifesciences price target lowered to $70 from $76 at Evercore ISI
- Edwards Lifesciences price target lowered to $77 from $83 at Citi